antibody deficiency

antibody deficiency

A nonspecific term which encompasses both agammaglobulinemia and hypogammaglobulinemia, regardless of whether the deficiency is an isolated phenomenon or the age of onset.
References in periodicals archive ?
Key factors driving the market growth include approvals for IVIG therapy from FDA, EMA, and government, increase in awareness about IVIG treatment, rise in incidence of antibody deficiency diseases & hemophilic patients, and emergence of technologically advanced IVIG products.
Intravenous immunoglobulins (IVIG) should be used if antibody deficiency is present.
FACU/ PLCG2 associated antibody deficiency and immune dysregulation (PLAID) is currently thought to be caused by deletions in PLCG2 .[5] PLAID is characterized by CU, autoimmunity, recurrent bacterial infection, and skin granuloma formation.
Moreover, duodenal biopsy organ culture has proven to be helpful in solving diagnostic dilemmas when gluten-related disorders are suspected and in particular when histology and serology are inconclusive, a GFD is started before adequate diagnostic work-up or even in antibody deficiency syndromes.
Clinical associations of biallelic and monoallelic TNFRSF13B vriants in Italian primary antibody deficiency syndromes.
Litzman, "When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach," Clinical and Experimental Immunology, vol.
XLA is an inherited immunodeficiency disorder characterized by the absence of mature B cells, resulting in a severe antibody deficiency and recurrent infections.
reported the distribution pattern of PID in the same tertiary care unit in Mumbai, which varied considerably from those reported by United States, Europe, Africa, and other Asian countries, as follows: diseases of immune dysregulation (29%), phagocytic defects (29%), predominant antibody deficiency (13%), combined T and B cell deficiency (19%), and other well-defined diseases (10%) (17).
Sensorineural hearing loss in primary antibody deficiency disorders.
The global primary immunodeficiency diseases market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the disease types (antibody deficiency - agammaglobulinaemia, common variable immune deficiency, IgG subclass deficiency, SIgAD; cellular immunodeficiency - ataxia telangiectasia, DiGeorge syndrome, hyper IgM syndromes, Wiskott-Aldrich syndrome; innate immune disorders - complement deficiencies, and hyper IgE syndrome) and test types (blood and prenatal testing), treatment types (immunoglobulin replacement therapy, antibiotics therapy, stem cell and gene therapy, etc.), and forecasts growth trends (CAGR% - 2016 to 2020).
Immunoglobulin products are used to treat primary antibody deficiency, complex immune deficiency disorders, and life threatening infections.
Asymptomatic individuals with greater than 1 subclass deficiencies defined as levels greater than 2 standard deviations below the age- dependent mean do not require treatment; they represent 2.5% of the normal population.7 Patients with severe recurrent respiratory tract infections meningitis an IgG subclass deficiency and a selective antibody deficiency are candidates for treatment.